Julie Kennedy Lesch: Driving Progress for People Living with Sickle Cell Disease
Julie Kennedy Lesch, Director at Center for Sickle Cell Disease Initiatives, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Proud to share this important article from our Sickle Cell Disease Task Force at the American Society of Hematology (ASH) outlining a collective commitment to advancing care, research, and policy for individuals living with sickle cell disease.
Although sickle cell disease affects more than 7 million people globally, it remains under-resourced and overlooked within health systems and research agendas.
This piece highlights how ASH and a broad coalition of stakeholders are working to change that through coordinated strategy, scientific rigor, and sustained investment in innovation.
Grateful to be part of a community pushing for measurable progress and better outcomes for people living with SCD worldwide.”
Title: ASH’s commitment to SCD: building on 10 years of progress
Authors: Alexander A. Boucher, Oladipo Bankole Cole, Payal C. Desai, Chancellor Donald, Titilope A. Fasipe, Charles T. Quinn, Julie Kennedy Lesch, Alexis A. Thompson
Read the Full Article on Blood Advances.
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Adrian Gottschlich: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis